Approval is not the end of testing. Phase IV trials, also called post-marketing studies, happen after a drug is on the market. They serve several purposes: to detect rare adverse effects that trials were too small to catch, to study the drug in populations that were excluded from pre-approval trials, to compare the drug to other treatments in real-world settings, and to test new formulations or additional indications. Some Phase IV trials are required by regulators as a condition of approval. Others are conducted voluntarily by companies.

The size and design vary widely. Some are large observational studies that follow patients for years. Others are randomized trials that test a new indication or a different dose. Because the drug is already approved, Phase IV trials can enroll a broader range of patients, including the elderly, pregnant women, and those with multiple conditions. This real-world evidence complements the controlled data from Phase III. If a serious safety signal emerges, regulators can require label changes, restrictions, or withdrawal.

What Phase IV studies do:

• Detect rare adverse events. Trials are too small to catch events that occur in 1 in 10,000 patients.
• Study real-world use. How the drug performs outside controlled trials.
• Compare treatments. Head-to-head studies against other drugs.
• Test new indications. Expanding the approved uses.
• Monitor long-term safety. Effects that emerge after years of use.

Post-marketing surveillance is a key part of pharmacovigilance, and Phase IV trials are one tool among many.